A multiparticulate pharmaceutical dosage form formed of particles comprising one or more populations of sustained release beads (SR) and / or one or more populations of timed pulsatile release beads (TPR) of at least one weakly basic drug, in which The weakly basic drug comprises a pharmaceutically acceptable nitrogen-containing drug (N), or a pharmaceutically acceptable salt thereof, which has a pKa in the range of about 5 to 14 and a solubility of no more than about 200 µg / ml at pH. 6.8, and at least one pharmaceutically acceptable organic acid in which said SR beads comprise core particles containing organic acid coated with an inner barrier coating on which the weakly basic drug is stratified and further coated with a membrane of SR, wherein said TPR beads comprise core particles containing organic acid coated c on an inner barrier coating on which the weakly basic drug is stratified and also coated with a temporary delay membrane, so that the weakly basic drug and organic acid are not in mutual contact in the dosage form and so that the organic acid and the weakly basic drug exhibit comparable release profiles.Una forma de dosificación farmacéutica multiparticulada formada por partículas que comprenden una o más poblaciones de perlas de liberación sostenida (SR) y/o una o más poblaciones de perlas de liberación pulsátil temporizada (TPR) de al menos un fármaco débilmente básico, en la que el fármaco débilmente básico comprende un fármaco que contiene nitrógeno (N) farmacéuticamente aceptable, o una sal farmacéuticamente aceptable del mismo, que tiene un pKa en el intervalo de aproximadamente 5 a 14 y una solubilidad de no más de aproximadamente 200 &mu；g/ml a pH 6,8, y al menos un ácido orgánico farmacéuticamente aceptable en la que dichas perlas de SR comprenden partículas núcleo que contienen ácido orgánico revestidas con un revestimiento de barrera interior sobre el que se estratifica el fármaco débilmente básico y se revisten además con una membrana de SR
